Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Vivos Therapeutics (NasdaqCM:VVOS) Q3 2025 Earnings Call November 19, 2025 05:00 PM ET Company ParticipantsBrad Amman - CFOKirk Huntsman - Chairman and CEOConference Call ParticipantsRobert Sassoon - Senior Research AnalystLucas Ward - Senior Research AnalystOperatorGood day, everyone, and welcome to the Vivos Third Quarter 2025 Conference Call. At this time, participants are in a listen-only mode. A question-and-answer session will follow the management's remarks. This conference call is being recorded, an ...

Vivos Therapeutics (NasdaqCM:VVOS) Q3 2025 Earnings Call November 19, 2025 05:00 PM ET Company ParticipantsBrad Amman - CFOKirk Huntsman - Chairman and CEOConference Call ParticipantsRobert Sassoon - Senior Research AnalystLucas Ward - Senior Research AnalystOperatorGood day, everyone, and welcome to the Vivos Third Quarter 2025 conference call. At this time, participants are in a listen-only mode. A question-and-answer session will follow the management's remarks. This conference call is being recorded, an ...

Financial Data and Key Metrics Changes - For Q3 2025, revenue increased by 76% to $6.8 million compared to $3.9 million in Q3 2024, and 78% sequentially from Q2 2025 [7][9] - For the nine months ended September 30, 2025, revenue increased by approximately $2.3 million, or 20%, to $13.6 million compared to $11.3 million for the same period in 2024 [9][12] - Gross profit for Q3 2025 increased by approximately $1.6 million to $3.9 million, with gross margin slightly decreasing to 58% from 60% in Q3 2024 [11][12] Business Line Data and Key Metrics Changes - The increase in revenue was driven by a $2.2 million increase in OSA sleep testing services primarily from the Sleep Center of Nevada, and $1.3 million from new treatment centers [8][9] - VIP enrollment revenue from the legacy business model decreased by $800,000, indicating a shift towards the new business model [9][10] Market Data and Key Metrics Changes - The company is currently servicing significantly less than 40% of the potential new patients being tested each month at the Sleep Center of Nevada, indicating substantial growth potential [24] - Over 210,000 OSA patients have been tested and seen by SCN providers since 2019, with many legacy patients potentially seeking alternatives to CPAP [24] Company Strategy and Development Direction - The strategic pivot towards acquiring sleep medical practices and forming alliances is aimed at increasing market penetration and financial returns [19][20] - The establishment of Sleep and Airway Medicine Centers (SAMHSA Centers) is part of the strategy to educate and evaluate patients for treatment options [22][30] Management's Comments on Operating Environment and Future Outlook - Management views Q3 2025 as a watershed quarter, indicating a significant inflection point in the company's ability to monetize its technology for treating sleep-related disorders [16][19] - The company expects revenue growth to outpace expenses as new teams are deployed and operational efficiencies are realized [23][33] Other Important Information - The company has secured $14.2 million in net cash from financing activities, which will support its growth initiatives [13] - General and administrative expenses increased by approximately $5.7 million, primarily due to costs associated with the Sleep Center of Nevada operations [12] Q&A Session Summary Question: How should sales be modeled for the next few quarters? - Management expects top-line revenues to continue to grow as new dental providers and nurse practitioners are added to the teams [35] Question: What is the expected ramp-up time for revenue generation? - A ramp-up period of approximately three to six months is anticipated to reach optimized revenue levels [36] Question: What are the expected contribution margins for SAMHSA operations? - Steady-state operations are expected to yield contribution margins of 50%-60% [38] Question: What is the goal for cash flow break-even? - The goal is to achieve cash flow break-even, with ongoing efforts to manage growth and operational expenses [39] Question: How should investors view the company now and in six months? - Management believes the company has finally found a monetization model that aligns with its technological advantages, indicating strong future growth potential [41][42]

Revenue Performance - Revenue for Q3 2025 was $6.8 million, a 78% increase sequentially and a 76% increase year-over-year compared to Q3 2024's $3.9 million[5] - Total revenue for the three months ended September 30, 2025, was $6,783 million, a significant increase from $3,860 million in the same period of 2024, representing a growth of 76.5%[21] - Product revenue reached $2,195 million for the three months ended September 30, 2025, compared to $1,958 million in 2024, marking an increase of 12.1%[21] - Service revenue surged to $4,588 million for the three months ended September 30, 2025, up from $1,902 million in 2024, reflecting a growth of 141.5%[21] Profitability and Loss - Gross profit for Q3 2025 was $3.9 million, reflecting an increase from $2.3 million in Q3 2024, while gross margin declined to 58% from 60% year-over-year[5] - Gross profit for the three months ended September 30, 2025, was $3,937 million, compared to $2,334 million in 2024, indicating an increase of 68.8%[21] - The operating loss for Q3 2025 increased to $4.7 million from $2.6 million in Q3 2024[5] - Operating loss for the three months ended September 30, 2025, was $(4,734) million, widening from $(2,645) million in the same period of 2024[21] - Net loss for the three months ended September 30, 2025, was $(5,400) million, compared to $(2,616) million in 2024, representing an increase in loss of 106.8%[21] - Net loss per share (basic and diluted) for the three months ended September 30, 2025, was $(0.49), compared to $(0.40) in 2024[21] Expenses and Financial Position - Operating expenses for Q3 2025 were $8.7 million, a 74% increase from $5.0 million in Q3 2024, primarily due to increased headcount and depreciation expenses related to the SCN acquisition[5] - Total operating expenses for the three months ended September 30, 2025, were $8,671 million, up from $4,979 million in 2024, reflecting a rise of 74.5%[21] - Cash and cash equivalents decreased to $3.1 million as of September 30, 2025, down from $6.3 million at the end of 2024[5] - Stockholders' equity was $2.5 million as of September 30, 2025, compared to $8.0 million at the end of 2024[5] Strategic Initiatives - The acquisition of The Sleep Center of Nevada contributed $2.2 million in diagnostic sleep testing revenue and $1.3 million in treatment center revenue during Q3 2025[5] - Vivos plans to expand its model into additional major markets beyond Las Vegas through acquisitions or contractual alliances with sleep medical practices[3] - The company is actively working to add new sleep optimization teams in 2026 to reduce cash burn and create potential for profitable operations[4] - Vivos has entered into a management agreement with MISleep Solutions LLC to provide its treatments and services in Auburn Hills, Michigan, with patient services expected to begin in early December 2025[7] Shareholder Information - The weighted average number of shares outstanding (basic and diluted) increased to 10,963,590 for the three months ended September 30, 2025, from 6,615,320 in 2024[21] - Non-operating income (expense) included other expense of $(679) million for the three months ended September 30, 2025, compared to $(18) million in 2024[21]

Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic pr ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 7921 Southpark Plaza, Suite 210, Littleton, CO 80120 (Address of principal executive offices) (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Therap ...

Call scheduled for today, Wednesday, November 19, 2025, at 5:00 pm ETLITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today announced it p ...

Company Overview - Vivos Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders via live webcast, emphasizing the shift towards virtual meetings for improved accessibility and attendance [1][3]. Leadership and Structure - Kirk Huntsman serves as the Chief Executive Officer and Chairman of the Board of Directors, with Brad Amman acting as Chief Financial Officer and Secretary of the meeting [2]. Voting and Participation - Stockholders of record as of September 8, 2025, are eligible to vote either by proxy or virtually during the meeting, allowing for greater participation [3]. - Shareholders who have already submitted a proxy and do not wish to change their vote are not required to vote again, streamlining the voting process [4].

Core Insights - Vivos Therapeutics has released clinical data indicating that its FDA-cleared Daytime-Nighttime Appliance (DNA) provides significant relief for children suffering from ADHD and obstructive sleep apnea (OSA) [1][6] Company Overview - Vivos Therapeutics, Inc. specializes in developing and commercializing treatments for sleep-related breathing disorders, particularly OSA [1][9] - The DNA appliance is the only FDA 510(k) cleared non-surgical, non-pharmaceutical treatment for moderate to severe pediatric OSA in children aged 6-17 [2][10] Market Context - The diagnosed rates of ADHD in the U.S. have increased from approximately 2-3% in the 1980s to over 11% by 2022, while the prevalence of OSA in preschool children rose from 3-9% before 2014 to 13-20% by 2022 [3][4] - There is a strong correlation between pediatric OSA and ADHD symptoms, with up to 95% of pediatric OSA patients exhibiting attention deficits [4][6] Clinical Data Findings - In a recent dataset, children treated with the Vivos DNA appliance reported a 50% decrease in the Pediatric Sleep Questionnaire scores and a 58% decrease in symptoms related to sleep-disordered breathing and ADHD [6][7] - The clinical trial included 55 patients, with 48 completing the study, showing significant improvements in airway volume (+40%) and a reduction in OSA severity by 51.4% [7][8] Treatment Implications - The improvements in OSA and ADHD symptoms may enhance children's academic performance and overall quality of life, with most benefits observed within the first six months of treatment [8]